History

GHRP-6 came out of work by endocrinologist Cyril Bowers and chemist Frank Momany, whose 1984 Endocrinology paper described a synthetic hexapeptide that released growth hormone without opioid activity. Specific pituitary binding sites for the compound (SK&F 110679) were shown in 1989. The hunt for its receptor led to the 1996 cloning of GHS-R1a and, in 1999, the discovery of ghrelin as its natural ligand, recasting GHRP-6 as a ghrelin mimetic. Interest as an anti-aging or GH-replacement drug faded; it never gained approval. Since the 2010s Cuba's CIGB has repurposed it as CIGB-500 in early-phase cardiac and stroke trials.

GHRP-6 is one of the oldest synthetic growth-hormone-releasing peptides, and its basic pharmacology in humans is genuinely well understood: it raises growth hormone (GH) and it makes people hungry. What is missing is the part that actually matters for the claims attached to it. For muscle growth, fat loss, anti-aging, or disease treatment, there are no large, replicated human trials, and it has never been approved for any use anywhere.

What it is

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The D-form amino acids were deliberately added to make the molecule more stable and potent than the natural enkephalin-derived parent it was built from.

Mechanistically it is a growth hormone secretagogue and a functional ghrelin mimetic: it activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor ghrelin binds. That receptor signals through phospholipase C and intracellular calcium release to drive GH out of pituitary cells. This is a different pathway from GHRH (growth-hormone-releasing hormone), though the two act synergistically. GHRP-6 is historically important precisely because synthetic peptides like it released GH through an unknown receptor, which prompted the cloning of GHS-R1a in 1996 and, in 1999, the discovery of its natural ligand, ghrelin.

An important nuance that marketing tends to skip: in humans, GHRP-6 does not act as a standalone GH “switch.” Its GH effect substantially depends on intact endogenous GHRH. In one controlled study, blocking GHRH cut the GH peak from about 33.8 to 6.2 micrograms per liter. And because GHS-R1a also sits on appetite-regulating neurons in the hypothalamus, GHRP-6 produces strong hunger, which is its most consistent and reproducible non-GH effect.

The claims

On the gray market and in some wellness clinics, GHRP-6 is promoted for muscle growth, fat loss, faster recovery, better sleep, “anti-aging,” and joint or tendon healing. The implied logic is that nudging GH upward delivers the benefits of growth hormone without injecting GH itself. Separately, in legitimate research, it was once studied as a GH stimulation probe and a candidate for GH-deficiency states, and more recently Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) has developed it as CIGB-500 for cardioprotection after heart attack and, combined with epidermal growth factor, for acute ischemic stroke.

The evidence

The honest split is this: the human pharmacology is real but old and small, while the clinical-outcome evidence is thin or absent.

On pharmacology and short-term safety, the data are legitimate but modest. A 2013 study in nine healthy men characterized how the body handles a single intravenous dose, showing a short distribution half-life of roughly 7.6 minutes and an elimination half-life of about 2.5 hours. The 1998 study in nine healthy men established that GHRP-6’s GH effect requires endogenous GHRH, by showing a GHRH antagonist eliminated most of the response. A 2014 dose-escalation safety study in 18 healthy men (run by CIGB) reported an “acceptable safety profile” with no serious adverse events, though it was small, open-label, and conducted by the manufacturer.

On actual clinical outcomes, the evidence does not reach the bar the claims imply. The cardiac program (the AMIGOS study of CIGB-500 in acute heart attack) is a Phase 1-2, open-label trial with a target of about 20 patients, registered in 2014 with no results posted. The stroke work is a 2024 Phase I/II, non-blinded, randomized study in 36 patients that reported better survival and recovery scores, but it tested epidermal growth factor combined with GHRP-6, never GHRP-6 alone, so the effect cannot be attributed to GHRP-6 specifically; the authors themselves flag the small sample and unblinded design and call for a Phase III trial. The appetite effect, by contrast, has solid mechanistic backing from animal work, including a 2002 rat study showing GHRP-6 stimulated feeding through hypothalamic appetite circuits.

What is missing is decisive. There are no large, replicated randomized controlled trials for any clinical outcome, and no FDA- or EMA-registered efficacy program. The modern efficacy work is run by the single Cuban manufacturer that holds the patents, with no independent replication, which is a conflict-of-interest signal rather than confirmation. The popular bodybuilding and anti-aging claims have essentially no controlled human outcome evidence; they extrapolate from mechanism and animal data. Even a sympathetic 2017 review compiling the “cytoprotection” rationale was written largely by that same Cuban group.

So the grade is Preliminary human: genuine small-scale human pharmacology and safety data exist, plus early-phase efficacy trials, but the human evidence stops well short of proving the things GHRP-6 is sold for.

Safety and side effects

The most consistent effect is strong hunger, usually within about 20 to 30 minutes of dosing, driven by the same appetite neurons ghrelin acts on. Hormonally, GHRP-6 is known for causing transient rises in cortisol and prolactin, which makes it less GH-selective than newer agents such as ipamorelin; the exact magnitude of those rises is not precisely established here.

Short-term safety in the small available trials looked acceptable: the 18-subject dose-escalation study reported no serious adverse events, and the pharmacokinetic study noted no major safety signal. But these were small, brief studies. There is no long-term human safety data. Theoretical concerns for this drug class, including effects on insulin sensitivity and blood sugar, water retention, and the consequences of chronically elevated GH, are not well characterized for GHRP-6 specifically in humans. The bottom line is that long-term safety is unestablished. None of this is medical advice.

A separate, real-world risk is product quality: material sold outside approved channels is unregulated, and its identity and purity are unverified.

Legal and regulatory status

GHRP-6 is not approved by the FDA, EMA, or any major regulator for any indication. It is not a component of any approved drug and is not on the FDA’s 503A list of bulk substances eligible for compounding. Per the FDA’s 2019 warning letter to United Pharmacy, GHRP-2 and GHRP-6 “were not nominated with adequate support for FDA to evaluate the substances,” and compounding with them was cited as a violation; in practice it cannot be lawfully compounded for patients or marketed for human use in the United States.

This is a time-sensitive area. The FDA’s compounding categories were actively revised in 2025 and 2026, including an April 2026 action removing 12 peptides from Category 2 and scheduling advisory-committee review. GHRP-6 was not among those reclassified, but the status is worth re-checking. Abroad, there is no general therapeutic approval; the only active development is the Cuban CIGB-500 program, still in early-phase trials, which is not a marketing approval.

In sport, the World Anti-Doping Agency prohibits GHRP-6 at all times, in and out of competition, under Section S2.2.4 (“Growth hormone releasing factors”). The 2026 list names GHRP-6 explicitly alongside other GHRPs and growth-hormone secretagogues, and uses “including, but not limited to” language so coverage is not name-dependent. S2 substances are “non-specified,” carrying the strictest sanctions.

Gray-market vendors typically label it “for research use only / not for human consumption,” which is a legal fig leaf, not a quality or safety designation.

Bottom line

GHRP-6 reliably raises growth hormone and reliably causes hunger in humans, and that pharmacology is well documented, if old and small-scale. But for everything it is actually marketed or developed for, the human evidence is either absent or limited to tiny, mostly open-label, manufacturer-run trials with no replicated outcome data. It is unapproved everywhere, has no legal compounding route in the US, has no established long-term safety profile, and is banned in sport.

Evidence grade: Preliminary human.

GHRP-6: well-mapped pharmacology, unproven benefits